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Abstract
Tight junctions are the most apically localized part of the epithelial junctional complex. They regulate the
permeability and polarity of cell layers and create compartments in cell membranes. Claudins are structural
molecules of tight junctions. There are 27 claudins known, and expression of different claudins is responsible for
changes in the electrolyte and solute permeability in cells layers. Studies have shown that claudins and tight
junctions also protect multicellular organisms from infections and that some infectious agents may use claudins as
targets to invade and weaken the host’s defense. In neoplastic diseases, claudin expression may be up- or
downregulated. Since their expression is associated with specific tumor types or with specific locations of tumors
to a certain degree, they can, in a restricted sense, also be used as tumor markers. However, the regulation of
claudin expression is complex involving growth factors and integrins, protein kinases, proto-oncogens and
transcription factors. In this review, the significance of claudins is discussed in lung disease and development.
Tight junctions
Tight junctions are membranous structures present in
epithelial, endothelial and mesothelial cells [1,2] They
form barriers between cells in cell layers regulating dif-
fusion of molecules and ions through the intercellular
space [3]. They also form a fence separating the apical
part of the cell from other parts thus preventing mem-
brane proteins from mixing up with each other [3].
They play a part in the formation of cellular polarity
and attachment [2,3] (Figure 1). The barrier formed by
the tight junctions prevents pathogens from penetrating
through the epithelial layers thus serving as components
of innate immunity [4]. They also participate in the
immune defense by forming secluded areas such as the
brain, eye or testis, where they contribute to sealing
these tissues from the immune system [5,6]. Tight junc-
tional proteins also participate in regulation of cell dif-
ferentiation and proliferation [7].
Tight junctions consist on one hand of membrane
proteins mediating cell to cell contacts. They include
occludin, claudins, tricellulin and JAMs (junctional
adhesion molecules). Scaffolding proteins on the other
hand mediate signals from the surface to cytoskeletal
actin filaments and activate signaling cascades of the cell
[1,3]. They include ZO-1 (Zona occludens-1), ZO-2,
ZO-3, MAGI-1 (membrane-associated guanylate kinase
with inverted orientation-1), cingulin and MUPP1
(multi-PDZ domain protein 1) [1,3,7]. Membrane
proteins are divided in two groups, those with one
transmembrane domain (JAMs) and those with four
(claudins, occludin, tricellulin) [7]. The membrane pro-
teins contain sequences in their carboxyterminal end
with which they can attach to the scaffolding proteins
[7]. One such is the PDZ domain with which the mem-
brane proteins bind to ZO-1, ZO-2, ZO-3 or MUPP1
proteins [7,8]. Scaffolding proteins, like ZO-1 inhibit cell
proliferation by binding ZONAB (ZO-1 associated
nucleic acid binding protein) thus preventing its move-
ment to the nucleus [7]. Apg-2 (Albino and pale green
2), a protein involved in heat shock reaction, may
replace ZONAB from its association with ZO-1 thus
promoting its movement to the nucleus resulting in
increased proliferation [7,9] (Figure 2). Also ZO-2 influ-
ences cell proliferation by binding to transcription fac-
tors AP-1 (Activator protein 1) and SAF-B (Scaffolding
attachment factor B) [7].
Claudins
Claudins are proteins responsible for the regulation of
the paracellular permeability of cells [1,3]. They were
discovered in 1998 by Tsukida and Furuse [10] and cur-
rently 27 claudins are known to be expressed by mam-
mals[1,11]. In humans, claudin 13 is missing [12]. Based
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any medium, provided the original work is properly cited.on their sequence similarity they are divided into classic
and non-classic claudins [1,12]. The former include
claudins 1-10, 14, 15, 17 and 19 and the latter claudins
11-13, 16, 18 and 20-24 [1]. Claudins have four trans-
membrane domains, between these there are two extra-
cellular loops (EL1 and EL2) and between inner
transmembrane domains there is a short 20-residue
intracellular loop [1,12] (Figure 3). The intracellular car-
boxyterminal part contains the PDZ domains by which
scaffolding proteins attach to claudins [1,12]. The larger
EL1 loop influences paracellular charge selectivity and
the smaller EL2 binds the claudin molecule to the corre-
sponding one in the neighbouring cell [12]. Claudins
can associate with the same claudin or another one on
the same cell membrane or with the claudin of the
neighbouring cell [1,13]. Heterodimerization between
claudins can take place only between specific claudins,
for instance between claudin 1 and 4 but not between
c l a u d i n1a n d2[ 1 3 ] .I ng e n e r a l ,c l a u d i n s2 ,7 ,1 0 ,1 5
and 16 increase paracellular cation permeability by
forming pores in the tight junctions whereas claudins 4,
5, 8, 11, 14 and 18 have a sealing function [1].
Claudins in normal lung
Claudins 1, 3, 4, 5, 7, 8 and 18 are expressed in human
bronchi and bronchioles but there are discrepant reports
of the expression of claudin 2 [14-18]. In immunohisto-
chemical studies on formalin fixed human lung tissue
bronchial epithelial cells expressed claudins 2 [17,18].
Similarly, claudin 2 has been detected in mouse lung
[15]. However, in mRNA analysis of bronchial tissues it
was not found [14]. Claudin 2 has been detected in skin
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Figure 1 In an epithelial cell layer tight junctions (marked by
green) regulate the permeability of solutes and ions through
the paracellular space (a violet arrow pointing downwards).
Thus they function as barriers of the paracellular space and also
prevent pathogens from reaching the subepithelial tissues. Tight
junction also takes part in determining the polarity of epithelial cells
(red arrow). Since they are located in the apicolateral part of the cell
membrane they separate the apical part of the cell membrane (red)
from the lateral part (yellow) preventing membrane proteins from
these parts of mixing up with each other (the fence function).
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Figure 2 Interaction of claudins with scaffolding proteins ZO-1,
ZO-2, ZO-3, MUPP1, cingulin and ZONAB in tight junctional
structures. The arrows show interactions between specific
molecules. If ZONAB is released from the association with ZO-1 it
moves to the nucleus and binds to cyclin dependent kinase 4 (CDK
4) resulting in cellular proliferation. Apg-2 competes with ZONAB for
the same binding site in ZO-1 thus affecting the binding of ZONAB
to ZO-1 and releasing it to the nucleus. This is one example how
tight junction proteins may influence the functions of the cell
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Figure 3 Claudins are membranous proteins harbouring two
extracellular loops (EL-1 and EL-2) and one small intracellular
loop. The larger EL-1 loop regulates solute permeability and charge
selectivity while the smaller EL-2 loop establishes contacts with the
neigbouring cell. There are four transmembrane domains in claudin
molecules. By the carboxyterminal part the claudin molecule
attaches to the scaffolding proteins of the tight junctions.
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Page 2 of 11squamous cells and in enterocytes where it takes part in
absorption of D-vitamin from the intestine [19,20]. High
amounts of claudin 2 mRNA are found in kidney,
pancreas, stomach and liver tissues while neural and
lymphatic tissues lacked expression [21]. In the study of
Aung et al trace amounts of claudin 2 were found in
the lung but the source of the expression was not deter-
mined [21].
Claudin expression appears to be the same in larger
and smaller bronchi and there is no variation in claudin
expression as has been found in different parts of the
gut or kidney tubular segments [14,22,23]. Quantitative
differences may, however be present and claudins appear
to be located not only in the apical region of cells but
also on the lateral membrane [14]. Claudin 5 is consid-
ered to be expressed mainly in endothelial cells and it
takes part in the formation of the blood brain barrier
[24]. It appears to be involved in the sealing function of
endothelial barriers in others sites such as blood retinal
or blood testis barrier [5,6]. When claudin 5 was overex-
pressed in bronchial tranfectant cells it, however, made
the epithelium leakier while claudins 1 and 3 made it
tighter [14]. In rat alveolar cells, EGF stimulation
increased the transmembrane resistance with an
increased claudin 4 or 7 protein expression while clau-
dins 3 and 5 were associated with a leakier phenotype
[25]. Paradoxically then, claudin 5 appears to induce
loosening of the barrier both in bronchial and alveolar
cells [14,25].
In immunohistochemical studies on human alveolar
cells, claudins 3, 4 and 7 have been detected in type 2
alveolar cells while type 1 alveolar cells were negative
[17,18]. Rat alveolar epithelial cells expressed claudin 3,
4 and 7 mRNA but claudin 1 or claudin 5 mRNA were
not found even though claudin 5 was found in western
blot analysis in alveolar cells [25]. Rat type 2 alveolar
cells express more claudin 3 and type 1 cells more clau-
din 7 [16,26]. Thus there are inconsistencies regarding
claudin expression also in alveolar cells detected by
immunohistochemistry or mRNA analysis which may be
species specific, partly due to the method used or may
reflect extended half lives of proteins compared to RNA.
Inconsistent results between protein and mRNA levels
of claudins 1, 3 and 7 have also been detected in alcohol
induced lung changes in rats where the protein expres-
sion of these claudins increased while the mRNA levels
stayed the same [27]. In studies on claudin mRNA
expression in human lung tissues claudins 6, 9, 10, 11,
15 or 16 have not been detected [14,16]. Expression of
claudins in lung cells has been compiled in Table 1.
Claudins in embryonic development of the lung
Claudins are involved in embryogenesis and organogen-
esis and changes in their expression can be seen in the
organogenesis of the gut and kidney [23,28]. Claudin 15
serves as a target for tcf2 gene in zebrafish creating one
lumen instead of multiple ones [29]. Interestingly, clau-
din 15 knockout mice develop a megaintestine [30]. In
organogenesis, claudin expression is turned off in cells
taking part in epitheliomesenchymal transition [31]. In
embryonic development claudins regulate cellular
integrity, and create hydrostatic pressure differentials
maintaining integrity of cystic compartments [31,32].
Additionally, claudin 1 may have a role in right-left
patterning of the embryonic tissues [31]. In Xenopus,
claudin 5 is required for heart development [33].
There are five stages in lung organogenesis. In the
embryonic period, the tracheal bud forms. The pseudo-
glandular and canalicular periods are characterized by
branching morphogenesis giving rise to the bronchial
three while during the saccular and alveolar periods the
alveoli form[17]. In investigations on claudin expression
during these stages claudins 1,3,4, 5 and 7 can be
detected in bronchial epithelium during the pseudo-
glandular and canalicular periods [17]. Pretype alveolar
cells express claudins 3, 4, 5 and 7 but not claudin 1
[17]. In saccular and alveolar periods claudin 5 is lost
from alveolar cells but weakly present in bronchial
epithelial cells. Claudins 3, 4 and 7 show strong positiv-
ity in bronchial and alveolar cells while claudin 1 is
negative in alveolar pneumocytes [17].
Compared to lung development also kidney ureters
develops by first forming an ureteral bud followed by
branching morphogenesis. Like in the lung tracheal bud-
ding ZO-1 is required in ureter bud formation of rat tis-
sues [28]. Branching morphogenesis is promoted by
ezrin which is activated by growth factors EGF (Epider-
mal growth factor), HGF (Hepatic growth factor) or
interleukin-1alpha by tyrosine phosphorylation. MT-
MMP1 (Membrane type matrix metalloproteinase 1)
and MMP2 (Matrix metalloproteinase 2) are secreted on
tips of the epithelial branches and proliferation is higher
in epithelial cells in those areas [28]. Proteins of adher-
ence junctions such as E-cadherin, are expressed a bit
Table 1 Claudin expression in bronchial, alveolar and
mesothelial cells
Claudin protein or mRNA
expression
Reference
Bronchial cells 1,2 ,3, 4, 5, 7, 8*, 18* [14-18,81,82]
Alveolar cells
type 2
2, 3, 4,5,7, 18 1* [15-18,25-27,81]
Alveolar cells
type 1
1,3,4,5,7,8,18 [27,68,26]
Mesothelial cells 1,2, 3,5,7 [104,107]
* = only mRNA expression found
bold = both mRNA and protein expression found
normal text = only protein expression found
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Page 3 of 11earlier, however there is a gradual increase of claudin 3
and ZO-1 from day 3 to 5 in cultured ureteric buds
[28]. Anatomically, the branching morphogenesis in the
lung differs from the ureteric development in that in the
ureteral development there is no lateral branching [28].
Also EGF (Epidermal growth factor) seems to be impor-
tant for lung organogenesis, deletion of EGFR (Epider-
mal growth factor receptor) leads to impaired branching
and deficient alveolisation, and pneumocytes remain
immature [34].
Prealveolar fetal alveolar lung cells express claudin-1,
3, 4, 5, 7, 9, 10 and 18 mRNAs [16]. mRNAs for occlu-
din, JAM-1, ZO-1, ZO-2, and ZO-3 are also present
[16]. In experimental models on alveolar cell differentia-
tion undifferentiated fetal alveolar epithelial cells
increase their transepithelial resistance under the influ-
ence of cell culture medium containing dexamethasone,
8-bromo-cAMP and isobuthylmethylxanthanine and
transform to type 2 alveolar cells at the same time
increasing the claudin 5 and 18 mRNA levels and
decreasing claudin 1 mRNA [16]. On the other hand,
EGF stimulated fetal alveolar type 2 cells show a
decrease in claudin 5 and 3 mRNA but an increase in
claudins 4 and 7 mRNA while increasing their transe-
pithelial resistance and transforming to type 1 cells [25].
While such in vitro models may differ from physiologi-
cal conditions, changes in claudin expression apparently
modulate or follow phenotypic changes in lung bron-
chial or alveolar cells during organogenesis. Such studies
also emphasize EGF’s role in lung alveolar development.
Potential roles of claudins and tight junctions in
lung disease
Tight junctions are important for lung defense since
they function as a barrier for pathogens and other exo-
genous compounds preventing their penetration into the
interstitial tissues. Tight junctions may thus be consid-
ered as a part of the innate immune system. The epithe-
lial barriers of bronchi are, however, relatively leaky
with a comparatively low transmembrane resistance of
approximately 100 Ωcm2 compared to endothelial cell
junctions of the blood brain barrier which have a 1500-
2000 Ωcm2 barrier resistance [14,35]. The thickness of
the tight junctional belt in airway epithelia varies from
0.27 μmt o0 . 3 7μm depending on the cell type [36].
There are reports of fragmentation and thinning of the
tight junctional belt in diseases such as asthma and
focal proliferations and thinnings are described in lung
neoplasia such as bronchioloalveolar carcinoma [36].
Such changes are also seen in cell line studies induced
by cytokines [37]
Lungs are exposed to several pathogens and noxious
stimuli which may influence paracellular permeability of
bronchial airways, alveolar cells or endothelial barriers
in alveolar walls. Tobacco smoke makes tight junctions
leakier [36]. Carcinogenic compounds such as bentzpyr-
ene and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone
(NNK) influence claudin synthesis by upregulating tran-
scription factors like twist, snail or ZEB1 [38,39] result-
ing in downregulation of E-cadherin and claudins.
Exposure of lung BEAS-2B cells and cancer cell lines to
tobacco smoke leads to changes in claudin expression
[40]. In bronchial cells sampled from smoking COPD
patients and healthy smokers claudins and other tight
junction genes are downregulated [41]. Tobacco smoke
also induces the formation of reactive oxygen species. In
kidney epithelial MDCK (Madine-Darby canine kidney
strain) II cells, exposure to hydrogen peroxide leads to
bimodal changes in the transepithelial barrier permeabil-
ity with activation of ERK1/2 and p38 kinases, and a
decrease in occludin, claudin 1 and claudin 2 levels [42].
Such changes could also make the bronchial and alveo-
lar epithelium leakier and the airways more vulnerable
to damage caused by pathogens causing irritation and
chronic infection. On the other hand, an increase in
claudin 2 expression leads to lower transepithelial resis-
tance in MDCK I and II cells and formation of paracel-
lular water channels [43,44]. Generally air pollutants
influence the barrier function of airway epithelium. Par-
ticulate matter of less than 10 μm in diameter decreases
the transepithelial potential in airway epithelial cells
causing internalization of occludin and its dissociation
from ZO-1 [45].
Inflammation may affect the barrier function of tight
junctions. Several integrins and growth factors produced
by inflammatory cells influence synthesis or organization
of tight junction components leading to enhanced per-
meability and exposure of tissues to antigens [15,46,47].
Increased permeability of tight junctions is one factor
lying behind the pathophysiology of colitis ulcerosa and
Crohn’s disease [47]. Also in chronic bronchitis and
asthma airway epithelial cells are exposed to chronic sti-
mulation by integrins and growth factors predisposing
the bronchial wall to dysregulation of the epithelial bar-
rier function further provoking the chronic infection
[46,48-50].
Pathogens may influence tight junctions in two ways.
Several bacteria and viruses lower the transepithelial
resistance by decreasing the expression of tight
junctional proteins making it easier for pathogens to
penetrate the tissues. Rhinovirus downregulates the
transepithelial resistance of nasal epithelial cells by lower-
ing the mRNA expression of claudin 1, ZO-1, E-Cadherin
and occludin [51]. HIV-1 decreases the transepithelial
resistance in enterocytes and genital epithelial cells by
disrupting claudins 1, 2, 4, occludin and ZO-1 in tight
junctions and lowering mRNA expression of claudins 1,
2, 3, 4, 5, occludin and ZO-1 by cytokine involved
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through the leaky barriers [52]. Rotavirus in known to
loosen tight junctions in gut epithelial cells by decreasing
expression of claudin 3, occluding and ZO-1 [53]. Yersi-
nia enterocolica causes a redistribution of claudins 3, 4
and 8 in colonic HT29/B6 cells with a lowering of transe-
pithelial resistance and diminution of the protein expres-
sion of claudins 2, 3, 8 and 10 and ZO-1 [54].
Aggressive strains of E Coli cause dissociation of clau-
din 1, ZO-1 and occludin from cell membranes along
with a decrease in electrical transmembrane potential
[55]. Helicobacter pylori causes disruption of claudin 4
expression in tight junctions and its movement to the
cytosol in gastric epithelial cells and lowering of claudin
4 protein levels, an effect which is dependent on IL-1b
[56]. On the other hand, claudins may be used as recep-
tors or co-receptors in the invasion of bacteria and
viruses to cells and tissues. Claudins 1, 6 and 9 serve as
a co-receptors for hepatitis C for invading liver and
endothelial cells [57,58]. Claudin 1 also promotes den-
gue virus entry to cells [59]. Claudins also serve as
receptors for some bacterial toxins. A well known
example is Clostridium perfringens enterotoxin (CPE)
which binds to claudin 3 and 4 [60]. In experimental
studies this has been used to destroy claudin 3 and 4
expressing cancer cells with chemical modifications of
the toxin [60]. Interestingly, CPE has also been success-
fully used to destroy metastatic cells expressing claudin
4 in murine tissue [61]. Unfortunately, claudin 4 is
many times downregulated in metastatic tissues such as
metastatic breast carcinoma [62] or carcinoma metasta-
sis to the lung [63]. The frequent associations of clau-
dins as means and targets for spread of infections could
predict putative polymorphisms in claudin molecules.
Indeed, 50 variations have been found in the claudin 1
gene region some of which alter susceptibility to hepati-
tis C infection [64].
Mechanisms of pathogen entry and its association
with claudins have not been so extensively studied in
the respiratory tract. It, however, appears probable that
similar mechanisms apply to airway epithelia. Matrix
metalloproteinase 9 (MMP 9)decreases epithelial bar-
rier function in bronchial cells, and increases their vul-
nerability to adenovirus infection [65]. The cells show
disruption of regular membranous staining pattern of
claudin 1 and occludin and internalization of reactivity
following MMP9 treatment which could be restored by
tissue inhibitor of matrix metalloproteinase 1 (TIMP1)
[65]. Pseudomonas aeruginosa has been shown to
invade airway epithelial barriers by destroying tight
junctions [66]. Interestingly, Plasmodium falciparum
malaria affects lung endothelial cells by relocation of
Z O - 1f r o mt h ep l a s m am e m b r a n ea n dd o w n r e g u l a t i o n
of claudin 5 [67]. Thus also parasite infections may be
associated with tight junctional changes in the pul-
monary cells.
Claudins in lung injury and inflammation
ARDS (Acute respiratory distress syndrome) is due to
injury of alveolar cells the reasons of which may be mul-
tiple including septic infections and toxic chemicals.
Such injury leads to edema due to leakage of alveolar
epithelial cells. Since claudins regulate paracellular per-
meability of cell layers evidently changes in claudin
expression are involved in such disease. There are no
morphological studies on claudin expression by human
tissues in ARDS. Evidence of tight junctional protein
changes in ARDS can be obtained from animal experi-
ments or cell culture studies. In alveolar cells cultured
from septic rat lung a decrease of claudin 4, claudin 18
and occludin was found associated with a decrease in
transmembrane resistance [68]. In ventilator-induced
lung injury in mice the mRNA expression of claudin 4
increased after 3 hours [69]. Such a phenomenon
appears to be an adaptive mechanism to make the
alveolar layers tighter, since blocking specifically the
m R N As y n t h e s i so fc l a u d i n4b ys i R N Ao rC P El o w e r s
the transmembrane potential [69]. Similar results come
from experimentally induced pancreatitis in rats where
the mRNA levels of claudin 4, claudin 5 and occludin
decreased due to pancreatitis induced lung injury but
increased after administration of emodin, a chemical
suggested to enhance epithelial barrier function [70].
Such data emphasize especially the role of claudin 4 in
combating the abrogation of alveolar cell permeability in
lung injury. Also the expression of claudin 5 is impor-
tant for endothelial cell tightness and vascular perme-
ability. Acrolein present in tobacco smoke may cause
lung injury by influencing claudin 5 expression in
endothelial cells and mice more resistant to acrolein
have a better survival due to their increased expression
of claudin 5 mRNA transcripts [71].
Interestingly, protein kinase C delta inhibitor appeared
to inhibit sepsis induced lung injury, such as disruption
of lung tissue or development of edema [72]. In nasal
epithelial cells treatment of cells with protein kinase C
activator 12-O-tetradecanoylophospho-13-acetate led to
an increased transepithelial electrical resistance and
upregulation of claudin 1, ZO1, ZO2 and occludin [73].
It was shown that the upregulation of the tight junc-
tional proteins was due to activation of PKC lambda
and theta partly induced by the transcription factor
GATA 3 [73]. In fact, phosphorylation of threonine sites
in claudins by PKC or PKA may dislocate claudins from
cellular membranes resulting in changed tight junctional
properties [1].
Also in lung inflammation alterations in alveolar cell
permeability play a role. In experimental studies on
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nan disruption of claudin 2, claudin 4 and claudin 5
staining and ZO-1 was observed on cell membranes
[15]. Such disruption was partly reversed by blocking
TNFa suggesting that TNFa-induced chemotaxis of
inflammatory cells might contribute to attenuation of
tight junctional permeability in lung inflammation [15].
Additionally, alcohol which provokes patients to lung
inflammation and ARDS was shown in experiments on
rats to induce changes in claudin expression of alveolar
epithelial cells [27]. Chronic alcohol ingestion of rats led
to a decrease of claudin 1, 3 and 7 mRNA and protein
expression and an increase in claudin 5 mRNA in alveo-
lar epithelial cells resulting in an increased leakiness of
tight junctions in the lung [27]. Additionally, inflamma-
tory mediators like IL-1b or IL-6 decrease claudin 3 and
4 levels in amniotic membranes of mice making them
more permeable [74].
Respiratory distress leads to local hypoxia of the lung.
Hypoxia induces cytoskeletal disruption of alveolar
epithelial cells and decreases ZO-1 protein levels dislo-
cating occludin from the cell membrane [75]. Alveolar
epithelial cells do not show changes in claudin 3 or 5
protein expression, however [75]. Claudin 5 is known to
influence the permeability of endothelial cells. In experi-
ments performed on mice bEND.3 (brain-derived
endothelial) and retinal endothelial cells, suppression of
claudin 5 mRNA leads to a decrease in transepithelial
resistance of these cells [76]. On the other hand, in
experimental murine renal ischemia-reperfusion injury
there was a significant upregulation of claudin -1, -3,
and -7 genes and a slight downregulation of claudin-2
[77]. Additionally, when both of these cells suffer from
hypoxia a decrease in claudin 5 mRNA and a lowering
of transepithelial resistance was detected [76].
T h e r ea r eo n l yaf e ws t u d i e so nt h ei n f l u e n c eo f
inflammation on claudin expression in bronchial cells.
In well differentiated human airway epithelial cells
(HAE) from cystic fibrosis (CF) and non-CF patients,
combined treatment with IL-1b and TNFa led to a
decrease in transmembrane potential and tight junc-
tional barrier function, the changes appearing more
rapidly in CF cells [37]. In analysis of airway epithelial
cells the expression of claudins 1 and 4 were not altered,
however, there was a decrease in the protein expression
of ZO1 and JAM and upregulation of hyperphosphory-
lated occludin and ICAM1 [37]. The influence of these
cytokines appeared to be mediated by PKC/lambda [37].
Claudins in interstitial lung disease
Interstitial lung diseases are characterized by chronic
inflammation, fibrosis and damage to the lung parench-
yma [78]. They consist of seven entities which are classi-
fied both by histology and clinicopathologic features
[78]. In interstitial lung diseases, reports of claudin
expression in UIP (Usual interstitial pneumonia) are
present [18]. Changes in claudin expression mainly
involve the regenerative alveolar cells or cells which
have been replaced by metaplastic epithelia. In UIP
regenerative metaplastic alveolar, squamous or bronchial
epithelium shows strong reactivity for claudins 1, 2, 3, 4
and 7 compared to normal alveolar cells where only
claudins 3, 4 and 7 are present [18]. There is a weaker
reactivity for claudin 5 in such regenerative cells. In sar-
coidosis, metaplastic regenerative epithelium displays a
similar kind of reactivity in metaplastic cells as in UIP
[18]. The formation of metaplastic epithelium in UIP
probably is related to chronic inflammation and secre-
tion of growth factors and integrins in the disease [78].
A different pattern of claudin expression in regenerative
metaplastic cells compared to alveolar cells would lead
to focal changes in the permeability of alveolar walls
which is probably harmful for the function of the lung.
There is also increased vascularity, neovascularisation
and increased secretion of angiogenic factors in UIP
[18]. Endothelial cells of blood vessels display intensive
expression for claudin 5. According to some reports
VEGF may upregulate claudin 5 [79]. Such increased
staining may then be based on increased secretion of
VEGF in UIP. Expression of claudins in different lung
pathologies has been compiled in Table 2.
Lung tumors
Lung carcinoma cells contain tight junctions and their
number is inversely associated with patient prognosis
and aggressivity [80]. In lung tumor cell lines, variable
expression of claudins 1, 2, 3, 4 and 7 is found [40]. In
studies on lung tumor material different histological
tumor types vary in their claudin expression showing
up- or downregulation of different claudins compared
to normal bronchial cells or lung tissue [40,81-83]. In
the study of Moldway et al small cell lung carcinomas
show a 16 fold higher level of claudin 3 mRNA expres-
sion than normal lung tissue [82]. Claudin 4 mRNA is
upregulated to 3-4 fold level in squamous, adenocarci-
noma and small cell carcinoma compared to normal
lung [82]. Both adeno- and squamous cell carcinoma
showed a slight downregulation of claudin 1 mRNA
compared to normal lung and squamous cell carcino-
mas had a 2.7 fold level of claudin 1 mRNA than ade-
nocarcinomas [82]. Paschoud et al found an increase
in claudin 5 and a decrease in claudins 3, 4 and 7
mRNA in squamous cell carcinoma compared to nor-
mal bronchial cells and an increase in claudin 1 and a
decrease in claudin 5 compared to lung parenchyma
[81]. Compared to bronchial cells claudins 1, 3 and 4
and 7 were decreased and claudin 5 mRNA increased
in adenocarcinoma while when compared to lung
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din 5 decreased [81].
In immunohistochemical studies significant differences
have been detected in claudin 3 expression between
squamous cell and adenocarcinomas the latter displaying
stronger expression [40,82,83]. Some studies also report
significant differences in the expression of claudin 1, 4, 5
and 7 between these two tumor groups [81,82]. In the
study of Paschoud et al squamous cells and adenocarci-
nomas could be discriminated by the expression of clau-
dins 1 and 5 because adenocarcinomas displayed strong
positivity for claudin 5 and weak positivity for claudin 1,
while the opposite could be detected in squamous cell
carcinomas [81]. Chao et al studied claudin 1 expression
in adenocarcinoma and found that a low expression of
claudin 1 was associated with a worse survival in these
tumors both by immunohistochemistry and mRNA
expression [84]. Transfection of claudin 1 into CL1-5
lung carcinoma cells changed the cells to less invasive,
less metastatic and less mobile, and their morphology
changed to a more epithelial one [84]. Such changes
could also be reversed by blocking claudin 1 mRNA
expression by siRNA. Oligonucleotide microarray analy-
sis showed a twofold change in 773 genes due to claudin
1 overexpression involving different cellular functions
associated with signaling cascades, cellular associations,
apoptosis and cytoskeletal regulation. They, however,
found that claudin 1 overexpressing cells were able to
activate MMP2 [84]. Similar results of claudin expression
on MMP activities have been detected in other cell lines.
In colon carcinoma CaCo-2 cells, invasion induced by
claudin 4 overexpression was due to activation of both
MMP2 and MMP9 the mRNA expression of which also
increased at the same time [85]. Claudin 5 along with
claudins 2, 3 and 4 has been shown to activate matrix
metalloproteinases [86]. Claudin overexpression in can-
cer cells may thus be one factor promoting tumor spread.
The variable expression of claudins in histologically
different lung tumor types may be related partly to the
cell type it originates from [83]. On the other hand, sev-
eral growth factors and integrins modify claudin
expression and they expression may vary in different
types of lung tumors. EGF, for instance, inhibits claudin
2 expression while simultaneously increasing claudin 1,
3 and 4 expression and the transepithelial resistance
without affecting the levels of occludin or ZO-1 in
canine kidney cells [87]. In pneumocytes EGF upregu-
lates claudins 4 and 7 while 3 and 5 are decreased [25].
Activating EGFR mutations are known to exist in non-
small cell lung carcinoma and especially in adenocarci-
noma and bronchioloalveolar carcinoma[88]. In line
with this, claudins 1 and 4 show a high expression in
lung adenocarcinomas and bronchioloalveolar carcino-
mas and claudin 2 and 5 are lower [40,82]. Small cell
lung carcinomas also display a higher expression of
claudin 2 than adenocarcinomas [83]. Another mutation
common to lung cancer is K-Ras [88]. Such mutations
are present 15-30% of non small cell carcinomas [88]. In
kidney cells, overexpression of ras leads to claudin 1, 4
and 7 overexpression while claudin 2 decreases and
claudins 3 and 5 remain the same [89]. Similarly, some
non-small cell carcinomas have PTEN (phosphatase and
tensin homologue) mutations [90]. Inactivation or muta-
tions of PTEN leads to activation of PKB (Protein kinase
B) resulting in increased cell proliferation and inhibition
of apoptosis [91]. Knockdown of PTEN has been shown
to lead to a loss of polarization in colon carcinoma cells
and strong downregulation of claudins 1, 3, 4 and 8
[92]. Small cell carcinomas and large cell neuroendo-
crine carcinomas, however, express c-kit, and they har-
bor c-myc amplifications and p53 and ras mutations,
and loss of p16 and RB expression and their influence
o nc l a u d i ne x p r e s s i o ni sn o tk n o w n[ 9 3 ] .A d d i t i o n a l ,
several cytokines influence claudin expression and bar-
rier function of epithelial cells and may surely influence
also the expression of claudins in lung carcinomas [47].
EMT (Epitheliomesenchymal transition) is a process
where tumor cells attain mesenchymal features which
make it easier for them to invade and metastasize
[94,95]. It is regulated by transcription factors such as
snail, slug, twist and zeb1 [94-96]. In mouse mammary
epithelial cells snail induced EMT and at the same time
Table 2 Claudin expression changes in different lung pathologies
UIP* ARDS Inflammation Lung SQC** Lung AC** Lung SCC** Reference
CL1 ↑ ↔ ↑↔ ↔↔ ↔ [37,18,81,82,47,76,77]
Cl2 ↑ ↓ ↔↔ ↔↔ ↔ [15,18,81,82]
CL3 ↑ ↓ ↔↔ ↔↔ ↑ [18,81,82,82]
CL4 ↑ ↓ ↓↔ ↔↔ ↑↑ ↑ [15,18,37,68-70,81,82]
CL5 ↑↓ ↓ ↓ ↓ [15,68-70,81,82]
CL7 ↑↔ ↔ ↑ ↔ ↔ [18,81,82,82]
CL = Claudin; UIP = Usual interstitial pneumonia; ARDS = acute respiratory distress syndrome; SQC = Squamous cell carcinoma; AC = Adenocarcinoma; SCC =
Small cell carcinoma
* = arrows represent metaplastic alveolar cells
** = qtRNA results compared with lung tissue expression
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herin [97]. In lung carcinoma there was an inverse asso-
ciation between zeb1 and claudins 1 and 2 and between
twist and claudin 5 [63]. Metastatic tumors to the lung
also showed an inverse association between claudins 5
and 7 and twist [63]. These results show that a part of
claudin expression is regulated by EMT associated tran-
scription factors and that claudins are involved in EMT.
Also different PKCs which regulate claudin phosphory-
lation are overexpressed in cancer and may cause dysre-
gulation or relocation of claudins in tumor cells [98].
PKCε is considered an oncogene and influences cellular
motility and ras expression, and it is upregulated in lung
and breast cancer [98]. PKC and PKA influence subcellu-
lar distribution of claudin 1 in melanoma cells [99].
PKCa phosphorylates claudin 5 causing its disappearance
from cell membrane [100]. On the other hand, phosphor-
ylation of serine 194 of claudin 4 by aPKC is required for
tight junction formation in keratinocytes [101]. Claudin
phosphorylation may also affect barrier junction perme-
ability without changes in claudin distribution [101].
Claudins are in contact with scaffolding proteins like
ZO-1, ZO-2 and ZO-3 and through them with the cellular
cytoskeleton [102]. ZO-1 has been shown to recruit the
transcriptional factor ZONAB from cytoplasm thus pre-
venting its movement to the nucleus where it promotes
cell proliferation. ZO-2, on the other hand, is able to bind
AP-1 [103]. How the expression of different claudins influ-
ences the functions of such zona occludens proteins is not
known but it is possible that in cancer cells the relation
between claudins and zona occludens and other scaffold-
ing proteins is deranged leading to a dysregulation of tran-
scription factors such as ZONAB or AP-1. Clearly more
research is needed to understand the functions and conse-
quences of claudin expression in lung cancer.
Because claudins 3 and 4 are overexpressed in adeno,
squamous and small cell carcinomas [40,81-83] they
might be susceptible to CPE-mediated treatment. In a
recent publication Yao et al created a modified CPE
protein containing segments of pseudomonas aeruginosa
enterotoxin A [104]. Treatment of cell lines containing
claudin 4 induced apoptosis and cell destruction in
them[105]. CPE also causes dislocation of claudin 4
from the tight junction in ovarian carcinoma cells and
sensitizes them to chemotherapeutic drugs [105]. This
effect is achieved by using a modulated C- terminal
fragment of the CPE molecule in the treatment which is
able to bind to claudin 4 and cause tight junctional loos-
ening but harbours no toxic effects of the N-terminal
p a r to ft h em o l e c u l et h u se n a b l i n gab e t t e ri n f l u xo f
chemotherapeutic agents to the cancer tissue (105).
Such CPE mediated treatment could also be one option
in treatment of claudin 3 or 4 positive lung cancer.
Mesothelial cells and mesotheliomas
Mesotheliomas are malignant tumors with an aggressive
behavior. In pleural biopsies taken for malignant pleural
disease, there is often diagnostic difficulty to distinguish
mesotheliomas from metastatic adenocarcinomas or
reactive mesothelial cells. Several markers, such as calre-
tinin, DJ2-40, TTF1 and CEA, can be used in differential
d i a g n o s i s[ 1 0 6 ] .C l a u d i n sh a v ea l s op r o v e nt ob eo n e
putative means of making a differential diagnosis
between such entities [107-110].
In our study on metastatic adenocarcinomas and
malignant mesotheliomas claudins 1, 3, 4, 5 and 7 had a
lower expression in mesotheliomas suggesting that they
could serve as differential diagnostic markers [107]. In
mesothelioma subtypes, sarcomatoid and biphasic
mesotheliomas showed less expression for claudins than
epithelioid ones [107]. Non-neoplastic mesothelial cells
showed expression for claudin 2 and weak expression
for claudin 1, but no expression was found for claudins
3, 4, 5 or 7 [107]. In effusions claudins 3 and 7 signifi-
cantly distinguished malignant
Mesothelioma cells from metastatic adenocarcinoma
cells [108]. Reactive mesothelial cells were negative for
claudin 7 but showed infrequent claudin 1 and 3 expres-
sion. Thus also reactive mesothelial cells could be distin-
guished from metastatic cells in pleural effusions [108].
Metastatic ovarian carcinoma cells could also be distin-
guished from metastatic breast carcinoma cells by claudin
7, and generally, ovarian, endometrioid and cervical cancer
metastases could be distinguished from lung or breast ade-
n o c a r c i n o m a[ 1 0 8 ] .I nt h ea r r a ys t u d yb yD a v i d s o ne ta l
serous mesotheliomas showed a significantly lower expres-
sion of claudins 3, 4 and 6 than ovarian adenocarcinomas
speaking for a lower level of claudins in mesothelial
derived neoplasms [108]. Facetti et al determined that
especially claudin 4 could be used in differential diagnosis
between malignant mesothelioma and metastatic adeno-
carcinoma [110]. Since adenocarcinoma metastases many
times express claudin 4, CPE could potentially be used in
treatment of such adenocarcinoma metastases in pleural
cavity since benign mesothelial cells do not express this
tight junctional protein [110].
Claudins have not been studied in other disease states
of the mesothelium although it could be expected that
they play a role in derangements of pleural fluid home-
ostasis and in pleuritis. Exposure of mesothelial cell
monolayers to hydrogen peroxide lowers their transe-
pithelial resistance with a simultaneous decrease in
occludin and ZO-1 expression [111]. Thus oxidative
stress, involved in many diseases, such as inflammation,
may be one factor causing loosening of mesothelial bar-
riers. In line with this, a recent article showed that the
levels claudins 1, 3, 5 and 7 decreased and claudin 2
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tion [112].
Conclusion
The permeability of tight junctions in epithelia is an
important factor in several pulmonary diseases. Patho-
gens causing infections are many some of which may
act by downregulating claudins or causing their
deranged distribution inducing changes in tight junc-
tional permeability allowing pathogens to invade
through epithelial barriers. In lung disease the effect of
such pathogens on claudin expression or cellular distri-
bution is still mainly unelucidated and needs further
research. Alteration of claudin expression also plays an
important role in lung diseases such as COPD, asthma,
and ARDS. Influencing alveolar or endothelial perme-
ability by manipulation the expression of claudins (eg.
claudins 4 and 5) might be future targets in the treat-
ment of lung injury. Changes in the expression of clau-
dins are also seen in pulmonary neoplasia reflecting
complex changes in several genes related to tumor
growth, spread and differentiation producing a charac-
teristic expression patterns in histologically different
tumor types. In adenocarcinomas a proposed new classi-
fication will surely also change our perspectives on
assessment of claudins on the behavior of these tumors
[113]. In addition to claudin 3 and 4 which may have
therapeutic implications for tumor treatment in the
future, claudin 18 might also be a new target for anti-
body mediated therapy in lung cancer [114].
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